ARTV Stock Analysis: Buy, Sell, or Hold?
ARTV - Artiva Biotherapeutics, Inc. Common Stock
$9.73
0.37 (3.95%)
▲
5d:
+5.99%
30d:
+21.78%
90d:
+81.19%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Get Alerted When ARTV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ARTV shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ARTV shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ARTV is currently trading at $9.73, which is considered extended relative to its 30-day fair value range of $7.20 to $9.17.
Technical Outlook: Technically, ARTV is in a strong uptrend. Immediate support is located at $6.74, while resistance sits at $10.50. The stock is showing strong short-term momentum, up 4.0% recently.
Market Sentiment: ARTV has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $35.80 (+282.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ARTV is in a strong uptrend. Immediate support is located at $6.74, while resistance sits at $10.50. The stock is showing strong short-term momentum, up 4.0% recently.
Market Sentiment: ARTV has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $35.80 (+282.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$7.20 -
$9.17
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range (+6.1% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.0%)
- BULLISH: Trading 282.5% below Wall St target ($35.80)
Trading Range Analysis
30-Day Trading Range
$7.20 -
$9.17
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$6.74
Resistance Level
$10.50
Current Trend
Strong Uptrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.33
Wall Street Target
$35.80
(+282.5%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: June 23, 2026 2:57 PM ET
Data refreshes hourly during market hours. Next update: 3:57 PM
Data refreshes hourly during market hours. Next update: 3:57 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ARTV showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 64 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 62 BUY |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 61 BUY |
